Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr Tagawa on the PSMAddition Trial of Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI and ADT in PSMA+ mHSPC

October 29th 2025

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the design the PSMAddition trial of lutetium Lu 177 vipivotide tetraxetan plus ARPI and ADT in mHSPC.

Precision Strategies and Targeted Combinations in GU Oncology: Expert Insights From ESMO 2025

October 29th 2025

Experts highlight how precision medicine, biomarkers, and targeted combinations presented at ESMO 2025 are shaping the future of GU cancer treatment.

Saruparib Plus an ARPI Shows Activity, Tolerability in Metastatic Prostate Cancer

October 24th 2025

Saruparib plus an androgen receptor pathway inhibitor was safe and active in metastatic prostate cancer.

Dr Tagawa on the Rationale for Evaluating Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI and ADT in PSMA+ mHSPC

October 22nd 2025

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the background of a phase 3 trial of lutetium Lu 177 vipivotide tetraxetan plus ARPI and ADT in mHSPC.

Dr Saad on Long-Term Data With Radium-223 Plus Enzalutamide in mCRPC With Bone-Predominant Disease

October 22nd 2025

Pinpointing Pivotal Prostate Cancer Data With Drs Agarwal and Shore

October 21st 2025

Neeraj Agarwal, MD, FASCO, and Neal Shore, MD, FACS, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in prostate cancer presented during the 2025 ESMO Congress.

Alternative Docetaxel Regimen Plus Darolutamide/ADT Lowers Toxicity in mHSPC

October 21st 2025

A reduced docetaxel regimen helped lower rates of AEs when combined with daolutamide and ADT in mHSPC.

Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI/ADT Yields Superior PFS in PSMA+ mHSPC

October 19th 2025

Lutetium Lu 177 vipivotide tetraxetan plus an ARPI and ADT improved rPFS in metastatic hormone-sensitive prostate cancer.

Enzalutamide Plus Leuprolide Yields OS Benefit in High-Risk, Biochemically Recurrent Prostate Cancer

October 19th 2025

Enzalutamide plus leuprolide acetate led to a 40.3% lower risk of death vs leuprolide acetate alone in high-risk, biochemically recurrent prostate cancer.

Capivasertib Plus Abiraterone Acetate, Prednisone, and ADT Extends rPFS in PTEN-Deficient HSPC

October 19th 2025

Capivasertib plus abiraterone acetate, prednisone, and androgen deprivation therapy was active in PTEN-deficient de novo metastatic HSPC.

Dr Saad on Baseline Patient Characteristics From the Phase 3 PEACE-3 Trial in mCRPC

October 15th 2025

[The baseline patient population] represents what we see in the real world, with a median age of 73. [This] is older than what we see in [many] clinical trials.

Expanding Radioligand Options Redefine mCRPC Management and Individualize Patient Care

October 15th 2025

Alicia Morgans, MD, MPH, discusses the role of radioligand therapies for mCRPC and the importance of shared decision-making in prostate cancer management.

PEACE-3 Data Add to Expanding Evidence Clarifying Radium-223 Use in mCRPC

October 14th 2025

Alicia Morgans, MD, MPH, discusses data from the PEACE-3 trial that support the use of radium-223 plus enzalutamide in patients with mCRPC.

64Cu-SAR-bisPSMA Bests SOC 68Ga-PSMA-11 PET/CT in Detecting PSMA-Positive Prostate Cancer Lesions

October 14th 2025

64Cu-SAR-bisPSMA displayed a higher detection rate of PSMA-positive prostate cancer lesions vs 68Ga-PSMA-11 PET/CT in patients with low PSA levels.

Niraparib Plus AAP Could Represent New Standard Option for mCSPC With HRR Gene Alterations

October 14th 2025

The AMPLITUDE trial met its primary end point of rPFS with niraparib regimen vs placebo in metastatic castration-sensitive prostate cancer.

Tarlatamab Demonstrates Early Safety and Activity in DLL3+ Neuroendocrine Prostate Cancer

October 13th 2025

DeLLpro-300 data provide preliminary evidence for the safety and activity of tarlatamab in DLL3-positive neuroendocrine prostate cancer.

Dr Saad on the Rationale for the PEACE-3 Trial in mCRPC With Bone-Predominant Disease

October 8th 2025

Fred Saad, MD, discusses the rationale behind the long-term safety analysis for radium-223 dichloride and enzalutamide in metastatic castration-resistant prostate cancer with bone-predominant disease.

Personalization Drives Next Wave of Metastatic Castration-Sensitive Prostate Cancer Treatment

October 7th 2025

A panel of experts discusses the effort to personalize treatment approaches in metastatic castration-sensitive prostate cancer.

Five Under 5: Top Oncology Videos for the Week of 9/28

October 5th 2025

The top 5 OncLive TV videos of the week cover insights in lung cancer, and prostate cancer, myelofibrosis.

Dr Olmos on Evaluating HRR Alterations in mHSPC

October 1st 2025

David Olmos, MD, PhD, discusses the evaluation of homologous recombination repair alterations in metastatic hormone-sensitive prostate cancer.